NASDAQ:LQDA
Liquidia Technologies Inc. Stock News
$12.71
-0.0300 (-0.235%)
At Close: May 17, 2024
Daily Insider Ratings Round Up 4/7/20
01:56pm, Thursday, 09'th Apr 2020
Tables of the top insider purchases and sales filed with the SEC on 4/7/20, based on dollar value. Dollar values often do not equate with significance when it c
Liquidia to Present at the 19th Annual Needham Healthcare Conference
11:30am, Thursday, 09'th Apr 2020
RESEARCH TRIANGLE PARK, N.C., April 09, 2020 -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and.
Liquidia Technologies (LQDA) Gets a Buy Rating from Needham
02:53pm, Wednesday, 08'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company's shares closed
Liquidia Technologies (LQDA) Gets a Buy Rating from Needham
02:53pm, Wednesday, 08'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, to
Liquidia Technologies (LQDA) Receives a Buy from Needham
07:23pm, Wednesday, 11'th Mar 2020
Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company's shares closed
Liquidia Technologies (LQDA) Receives a Buy from Needham
07:23pm, Wednesday, 11'th Mar 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on Liquidia Technologies (
LQDA
–
Research Report
) today and set a price target of
$30.00
. The company’s shares closed last Monday at $3.60
Liquidia Reports Fourth Quarter and Full-Year 2019Financial Results and Provides Corporate Update
11:00am, Wednesday, 11'th Mar 2020
Submitted New Drug Application (NDA) for LIQ861 in January 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C., March 11,.
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
08:14pm, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
12:00am, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
Liquidia to Present at Cowen 40th Annual Health Care Conference
09:30pm, Wednesday, 26'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
Liquidia seeks pivotal FDA approval for lead drug
07:55pm, Monday, 27'th Jan 2020
Morrisville-based Liquidia has submitted its lead drug asset for potential approval by the U.S. Food and Drug Administration.
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology with the goal of enhancing deep-lung delivery using a convenient, palm-sized
Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
02:00pm, Friday, 24'th Jan 2020
LIQ861 is an inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology to enhance deep-lung delivery using a convenient, palm-sized dry powder inhaler (“DPI”) f
Will Liquidia Continue to Surge Higher?
12:29pm, Wednesday, 15'th Jan 2020
As of late, it has definitely been a great time to be an investor in Liquidia.
